Protagonist and Takeda Report Positive Phase 3 Results in Rare Blood Cancer at ASCO 2025 VERIFY study meets all endpoints in polycythemia vera, supporting improved hematocrit control, reduced need for phlebotomy, and symptom relief Protagonist Th

#PTGX and #TAK report positive Phase 3 results for rusfertide in rare blood cancer PV at ASCO 2025! The data shows major progress in symptom control and disease management.
#ProtagonistTx #TakedaPharma
#Biotech #ProtagonistTherapeutics #RareDisease #PVResearch
prismmarketview.com/protagonist-...

Exclusive: Global health funds push for more private money, fearing government retreat One of the world's biggest global health funders will ask the private sector for a steep increase in donations as concern of a shortfall in government contributions grows following a U.S. decision to exit the World Health Organization.

Contributions from private entities like
#TakedaPharma have been critical in the fight to end infectious diseases & strengthen health systems in LMICs. At #WEF25, #GlobalFund invited the private sector to build on these achievements & scale up their impact.

bit.ly/3QiQebP